Investor Relations

Investment Overview

CBMG's goal is to develop safe and effective cellular medicine therapies for indications that represent a large unmet medical need in China and the US.

scroll

Investment Highlights

  • 01

    NASDAQ-listed China biopharmaceutical company focused on immuno-oncology and degenerative diseases.

  • 02

    China, a large market: 4x US population; 5M new cancer patients annually plus 57M Knee Osteoarthritis patients.

  • 03

    A leading biopharmaceutical innovator developing proprietary CAR-T constructs and allogeneic stem cell therapies.

  • 04

    Cutting-edge R&D and GMP facilities expanding capacity.

  • 05

    Lower valuation than peers given development progress, growth catalysts and addressable market size.

  • 06

    Seasoned management team with scientific, regulatory and financial expertise.

  • 07

    A SEC accelerated filer and a Nasdaq Global Market company.

Our strategy is to commercialize both home grown and partnered cellular medicine technologies in a safe and efficient manner

and achieve a leading position in the China specialty pharmaceutical market for cell therapeutics. Our near term objective is to pursue successful clinical trials in China for our Stem Cell and Immuno-Oncology applications. By applying U.S. Standard Operating Procedures (SOPs) and protocols and following authorized treatment plans in China we are differentiated with a first mover’s advantage and a fortified barrier to entry from competitors.

We believe that few competitors in China are as well-equipped as we are in the clinical trial development, diversified U.S. FDA protocol compliant manufacturing facilities, regulatory compliance and policy making participation, as well as a long-term presence in the U.S. with U.S.-based management and investor base.

We intend to continue our business development effort by adding other proven domestic and international biotechnology partners to monetize the China health care market.